Meeting Materials. The JDC will consider all information that is material to an assessment of the status, direction and progress of the Development Program, including all clinical trials protocols, data and reports. The JDC Chair will ensure that minutes are prepared and distributed to each member of the JDC promptly after each meeting. Those minutes shall contain a report on the activities of the JDC during its meeting. CFFT’s representative on the JDC will receive all documents and information distributed or communicated to members of the JDC, and may review copies of all other information material to the development of a Drug Product Candidate unless the JDC denies access to that information for demonstrable competitive reasons.
Meeting Materials. Each Party will provide the members of the JDC with copies, which may be in electronic format, of all materials it intends to present at a JDC meeting. The JDC may also request at any time specific data or information related to Development activities or any other data to which the JDC is entitled under this Agreement or that a written report be prepared in advance of any meeting summarizing certain material data and information arising out of the conduct of the Development of Licensed Product or any other data to which the JDC is entitled under this Agreement and the Party or appropriate committee to whom such request is made shall promptly provide to the other Party or the JDC such report, data or information.
Meeting Materials. Progress review and technical review meeting materials will consist of power point presentations, technical data, marketing white papers, studies, technical specifications analyses and other reports. Meeting materials will be delivered to the [**].
Meeting Materials. The Potentiator JDC will consider all information that is material to an assessment of the status, direction and progress of the development program for VX-770, including clinical trial protocols, a summary of the IND package, enabling animal toxicity data reports, clinical trial protocols, clinical trials final reports, summary data and reports. The Potentiator JDC will review progress reports prepared by Vertex, which shall be submitted to the Potentiator JDC prior to each meeting and which shall include a summary in written text of progress made during the preceding three month period under the VX-770 Accelerated Potentiator Development Plan. The chemical structure of VX-770 will be disclosed at the written request of CFFT to one CFFT employee reasonably acceptable to Vertex who is a JDC member and who executes a customary form of confidentiality agreement directly with Vertex, undertaking to maintain the chemical structure in confidence. Vertex will also disclose the chemical structure of VX-770 to CFFT’s chemistry advisors to whom it has previously disclosed the structure, under confidential disclosure agreements previously executed with each such advisor, provided that such agreements explicitly cover the additional disclosure or are appropriately modified to that effect. The Potentiator JDC Chair will ensure that minutes are prepared and distributed to each member of the Potentiator JDC after each meeting. Subject to the restrictions on disclosure of chemical structures set forth above, CFFT’s representatives on the Potentiator JDC will receive all documents and information distributed or communicated to members of the Potentiator JDC. In any event, all information presented to the JDC or otherwise disclosed to CFFT by or at the direction of Vertex shall be deemed confidential to Vertex and subject to the confidentiality provisions of the Existing Agreement.
Meeting Materials. The IPT will consider all information that is material to an assessment of the status, direction and progress of the Development Program, including all clinical trials protocols, data and reports. The IPT Leader will ensure that full and complete minutes are prepared and distributed to each member of the IPT promptly after each meeting. Those minutes shall contain a full report on the activities of the IPT during its meeting. VERTEX's representative on the IPT will receive all documents and information distributed or communicated to members of the IPT generally, and may review copies of all other information relative to the development of a Drug Product Candidate unless the IPT Leader denies access to that information for good reason.
Meeting Materials. The Secretary shall deliver Election or Meeting materials to any Member who requests early voting or absentee ballot. If the Member wants someone else to represent their Membership at the Meeting, then submit an executed Proxy form to the Secretary, prior to the beginning of the meeting. The person named as the Member’s Proxy must attend.
Meeting Materials. At a time to be determined exclusively by LAC, LAC will prepare and will print and make available, directly or indirectly, copies of the Meeting Materials (and any necessary amendments, modifications or supplements to the Circular), together with any other documents required by Applicable Laws in connection with the Meeting, to all holders of LAC Common Shares and holders of other securities of LAC, if applicable, as required by the Interim Order and in accordance with Applicable Laws. Spinco will cooperate with LAC in all aspects of the preparation of the Circular, and any amendments, modifications or supplements thereto. LAC will cause the Meeting Materials and other documentation required in connection with the Meeting to be sent to each holder of Common Shares and filed as required by the Interim Order and Applicable Laws. Each Party will cause the Circular to be prepared and delivered in compliance, in all material respects, with the Interim Order and Applicable Laws, and provide the LAC Shareholders with sufficient information to permit the LAC Shareholders to form a reasoned judgment concerning the matters to be placed before the Meeting. The Parties will ensure the Circular does not, at the time of its mailing, contain any Misrepresentation and each Party will promptly notify the other Party if it becomes aware that the Circular contains a Misrepresentation or otherwise requires an amendment, modification or supplement, in which case Spinco will cooperate with LAC in the preparation of any such amendment, modification or supplement as LAC may require or request. LAC may, in its sole discretion elect to send Meeting Materials in accordance with section 9.1 of National Instrument 51-102 Continuous Disclosure Obligations or alternatively use "Notice and Access" as contemplated by section 9.1.1 of such instrument.
Meeting Materials. Parent and SpinCo shall prepare and Parent shall file with the SEC and, if applicable, with the Canadian Securities Authorities and/or TSX a preliminary proxy statement/management circular, and Parent and SpinCo shall subsequently prepare, file and mail (as applicable) the Meeting Materials to the holders of Parent Common Shares, and such amendments, supplements or response letters thereto, in each case, in accordance with applicable Law and the Arrangement Agreement (for clarity, including the use of “notice and access”).
Meeting Materials. Without limiting the generality of Section 3.3(e), each party shall co-operate with the other in the preparation of any notice of meeting, management information circular, proxy circular or other documents to be prepared in connection with meetings of holders of Granite GP Common Shares and Granite REIT Unitholders, including by providing any necessary information to be included in such documents, and in the mailing, filing or other dissemination or publication of such materials in accordance with applicable law.
Meeting Materials. Gather meeting materials and ship to hotel. Distribute final program electronically to all registered meeting attendees two weeks prior to each meeting. • Meeting Evaluation Form – Develop and distribute to attendees at WEFMAX. • Post WEFMAX – Post presentations, summary and fact sheets on web within two weeks after each WEFMAX meeting.
